Pulmonx (LUNG) Stock Price, News & Analysis

Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $1.71 to $1.87
• 50-Day Range: $1.51 to $3.78
• 52-Week Range: $1.47 to $9.37
• Volume: 425,339 shs
• Average Volume: 455,058 shs
• Market Capitalization: $76.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.66
• Consensus Rating: Moderate Buy

Pulmonx Stock Analysis - MarketRank™

Pulmonx scored higher than 79% of companies evaluated by MarketBeat, and ranked 225th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pulmonx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmonx is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmonx is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmonx has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.61% of the float of Pulmonx has been sold short.

Short Interest Ratio / Days to Cover

Pulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmonx does not currently pay a dividend.

Dividend Growth

Pulmonx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.61% of the float of Pulmonx has been sold short.

Short Interest Ratio / Days to Cover

Pulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.61

News Sentiment

Pulmonx has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Pulmonx this week, compared to 2 articles on an average week.

Search Interest

Only 11 people have searched for LUNG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Pulmonx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulmonx insiders have sold 90.64% more of their company's stock than they have bought. Specifically, they have bought $71,362.00 in company stock and sold $136,044.00 in company stock.

Percentage Held by Insiders

Only 6.80% of the stock of Pulmonx is held by insiders.

Percentage Held by Institutions

91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LUNG Stock Analysis - Frequently Asked Questions

How have LUNG shares performed this year?

Pulmonx's stock was trading at $6.79 at the beginning of the year. Since then, LUNG stock has decreased by 72.5% and is now trading at $1.87.

How were Pulmonx's earnings last quarter?

Pulmonx Corporation (NASDAQ:LUNG) posted its earnings results on Wednesday, July, 30th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative trailing twelve-month return on equity of 69.76%.
Read the conference call transcript.

When did Pulmonx IPO?

Pulmonx (LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Pulmonx's major shareholders?

Pulmonx's top institutional shareholders include Primecap Management Co. CA (12.67%), JPMorgan Chase & Co. (1.45%), Bank of America Corp DE (1.18%) and Connor Clark & Lunn Investment Management Ltd. (0.54%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Daniel P Florin, Richard Ferrari, John Mckune and Alissa Hsu Lynch.
View institutional ownership trends.

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulmonx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 8/27/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LUNG
• CIK: 1127537
• Web: pulmonx.com
• Phone: 1-650-364-0400
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pulmonx: $7.66
• High Price Target: $16.00
• Low Price Target: $2.50
• Potential Upside/Downside: +320.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.39 million
• Net Margins: -62.88%
• Pretax Margin: -62.28%
• Return on Equity: -69.76%
• Return on Assets: -36.26%

Debt

• Debt-to-Equity Ratio: 0.54
• Current Ratio: 5.35
• Quick Ratio: 4.63

Sales & Book Value

• Annual Sales: $83.79 million
• Price / Sales: 0.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.70 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 40,750,000
• Free Float: 37,976,000
• Market Cap: $74.37 million
• Optionable: Optionable
• Beta: 0.43